PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.07%
R&D change of 37.07% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
-49.28%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
3.11%
Other expenses change of 3.11% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
2.64%
Operating expenses growth while Biotechnology reduces costs. Peter Lynch would examine differences.
2.64%
Total costs growth while Biotechnology reduces costs. Peter Lynch would examine differences.
-60.43%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
3.11%
D&A change of 3.11% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
0.38%
EBITDA change of 0.38% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-2.64%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
70.91%
Other expenses change of 70.91% versus flat Biotechnology. Walter Schloss would verify control.
0.38%
Income change of 0.38% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-60.43%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
0.38%
Net income growth 50-75% of Biotechnology median of 0.65%. Guy Spier would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
3.04%
EPS growth below 50% of Biotechnology median of 6.90%. Jim Chanos would check for deterioration.
3.04%
Diluted EPS growth below 50% of Biotechnology median of 6.90%. Jim Chanos would check for deterioration.
2.54%
Share count reduction below 50% of Biotechnology median of 0.43%. Jim Chanos would check for issues.
2.54%
Diluted share reduction below 50% of Biotechnology median of 0.47%. Jim Chanos would check for issues.